Status Migrainosus
Status migrainosus is a debilitating migraine attack lasting >72 hours continuously, with pain that is severe and refractory to standard outpatient treatment. It often leads to dehydration, sleep deprivation, and medication overuse, creating a self-perpetuating cycle. Management typically requires ED treatment or inpatient admission with IV therapy, most importantly IV dihydroergotamine (DHE) protocol.
Bottom Line
- Definition: Migraine attack lasting >72 hours with severe, unremitting pain (brief relief with sleep or medication is allowed)
- IV DHE (Raskin protocol) is the most effective treatment — 89% headache-free within 48 hours in the original trial
- Rehydration + IV antiemetic + IV ketorolac first, then initiate DHE
- Rule out secondary causes if the presentation is atypical — prolonged migraine with new features warrants imaging
- Bridge to prevention: Use the admission to start or optimize preventive therapy before discharge
- High recurrence risk: ~30% recur within 30 days; steroid bridge and early follow-up are essential
ICHD-3 Criteria
- A migraine attack fulfilling criteria for migraine without aura or migraine with aura, except for duration
- Headache lasting >72 hours
- Pain and/or associated symptoms are debilitating
- Remissions of up to 12 hours due to medication or sleep are permitted
- Not better accounted for by another ICHD-3 diagnosis
Initial ED Management
Before initiating DHE, address the acute symptoms and complications:
- IV fluid resuscitation: Most patients are dehydrated from vomiting and poor oral intake; 1-2 L normal saline
- IV antiemetic: Metoclopramide 10-20 mg or prochlorperazine 10 mg + diphenhydramine 25 mg
- IV ketorolac 15-30 mg: Analgesic bridge while setting up DHE (use 15 mg in elderly or renal impairment)
- Dexamethasone 10 mg IV: Reduces recurrence and may facilitate breaking the cycle
- Reassess: If initial treatment resolves the headache, discharge with rescue plan. If headache persists, proceed to DHE
IV Dihydroergotamine (DHE) Protocol
Raskin Protocol (Modified)
The Raskin protocol remains the gold standard for inpatient treatment of status migrainosus and refractory migraine. The DHE IV for Intractable Migraine trial demonstrated 89% of patients became headache-free within 48 hours, with shorter hospital stays compared to controls.
| Step | Details |
|---|---|
| Pre-treatment | Antiemetic 30 minutes before each DHE dose (metoclopramide 10 mg IV or ondansetron 4 mg IV). DHE causes significant nausea without pre-treatment. |
| Test dose | DHE 0.5 mg IV over 2-3 minutes. Monitor for chest tightness, leg cramping, or blood pressure changes. |
| Standard dosing | DHE 0.5-1 mg IV every 8 hours. Adjust based on response and tolerability. Most centers use 1 mg per dose. |
| Duration | Continue for 3-5 days or until headache-free for 24 hours (whichever comes first). Most patients respond within 48 hours. |
| Maximum dose | 3 mg per 24 hours; 20 mg per treatment course |
Continuous DHE Infusion (Alternative)
Some specialized headache centers (Jefferson, Mayo) use continuous IV DHE infusion rather than intermittent dosing:
- Protocol: 0.5 mg/hour continuous infusion for 3-4 hours, repeated every 12 hours
- Rationale: May provide more consistent CGRP suppression; some patients tolerate better than bolus dosing
- Limited comparative data but increasingly used for refractory cases
Contraindications to DHE
- Coronary artery disease, peripheral vascular disease, uncontrolled hypertension
- Pregnancy or breastfeeding
- Triptan use within the preceding 24 hours
- Basilar or hemiplegic migraine (consensus-based)
- Hepatic or renal impairment (DHE is hepatically metabolized)
- Concurrent use of potent CYP3A4 inhibitors (azole antifungals, protease inhibitors, macrolide antibiotics)
DHE Practical Tips
- Nausea is the limiting side effect — always pre-medicate; if nausea persists, switch antiemetic or reduce DHE to 0.5 mg
- Chest tightness and leg cramps can occur; usually mild and self-limited. Discontinue if severe.
- Monitor blood pressure every 8 hours during infusion; hold if SBP >180 or DBP >110
- Obtain baseline ECG in patients >40 or with vascular risk factors
- Expect improvement within 48 hours — if no response after 3-4 DHE doses, reassess diagnosis and consider alternatives
Pain Management During DHE Protocol
Patients often ask about pain control while waiting for DHE to work. Managing expectations is key:
Approach to Pain During Admission
- Set expectations: Explain that DHE works gradually over 24-48 hours; the goal is breaking the cycle, not immediate complete relief
- Scheduled acetaminophen: 1000 mg every 6 hours is a safe, non-interfering adjunct
- Ice packs, dark room, sleep hygiene: Non-pharmacologic measures help and should be encouraged
- Avoid opioids: Opioids interfere with DHE efficacy, promote MOH, and increase length of stay. Counsel patients that opioids are not used for migraine management in most headache centers.
- When opioids are considered: Only in rare circumstances — true DHE failure, DHE contraindications with no alternatives, or overwhelming patient distress. If used, limit to short-acting agents for 24-48 hours maximum.
- Nerve blocks: Greater occipital nerve block can provide several hours of relief and is safe during DHE protocol
Alternatives When DHE Is Contraindicated
| Agent | Dose | Evidence |
|---|---|---|
| IV valproate sodium | 500-1000 mg IV over 30 min, can repeat every 8h | Several case series show benefit; avoid in pregnancy and liver disease |
| IV eptinezumab | 100-300 mg IV (single dose) | Preventive CGRP mAb but IV route provides rapid onset (Day 1 effect in PROMISE-2); increasingly used off-label for refractory acute migraine at specialized centers |
| IV lidocaine infusion | 1-2 mg/min continuous (requires telemetry) | Used at some headache centers for refractory cases; requires cardiac monitoring; limited RCT data |
| IV magnesium | 2 g bolus, then 1 g/h infusion for 6-12h | Adjunctive benefit; well-tolerated; best evidence in migraine with aura |
| Ketamine (sub-anesthetic) | 0.1-0.5 mg/kg/h infusion | Case series in refractory status migrainosus; NMDA antagonist mechanism; dissociative side effects limit use |
| Greater occipital nerve block | Bupivacaine 0.5%, 2-3 mL bilateral | Useful adjunct; can be performed at bedside during admission; repeatable |
IV Eptinezumab for Acute Status Migrainosus
- While FDA-approved only for prevention, the IV route provides rapid onset — PROMISE-2 showed significant effect on Day 1 post-infusion
- Mechanistically rational: blocks CGRP immediately, unlike SC mAbs which take days-weeks
- Some specialized headache centers now use eptinezumab 100-300 mg IV as rescue for refractory status migrainosus
- Advantages: No cardiovascular contraindications; single-dose administration; also provides ongoing prevention
- Limitations: Off-label for acute use; expensive; insurance coverage challenges
- May be particularly useful in patients with CV contraindications to DHE who also need long-term prevention
Steroid Bridge Therapy
Used to prevent early recurrence after breaking status migrainosus:
- Dexamethasone: 4 mg BID for 3-4 days, then taper over 3-4 days
- Prednisone: 60 mg daily for 5 days, then taper (alternative approach)
- Evidence is limited but widely used in practice
- Useful bridge while waiting for preventive therapy to take effect
Inpatient Admission Criteria
When to Admit
- Status migrainosus not responding to ED-level treatment (dopamine antagonists, ketorolac, single DHE dose)
- Severe dehydration or intractable vomiting requiring ongoing IV fluids
- Need for multi-day IV DHE protocol
- Concurrent medication overuse withdrawal requiring supervised taper (particularly opioids or barbiturates)
- Diagnostic uncertainty requiring inpatient workup
- Psychiatric comorbidity requiring concurrent management (suicidal ideation from intractable pain)
Post-Discharge Recurrence
Status migrainosus carries a high recurrence risk. Understanding predictors helps target prevention:
- 30-day recurrence rate: ~25-35% in most series
- Predictors of recurrence:
- Concurrent medication overuse headache (strongest predictor)
- Depression or anxiety
- No preventive therapy initiated at discharge
- Longer duration of status migrainosus before treatment
- History of prior status migrainosus
- Protective factors: Starting CGRP mAb or onabotulinumtoxinA during admission; successful MOH withdrawal; psychiatric treatment optimization
Discharge Planning
- Start or adjust preventive therapy before discharge — the inpatient setting is an opportunity to initiate CGRP mAb, start onabotulinumtoxinA, or load a preventive (e.g., valproate, topiramate)
- Steroid taper for 5-7 days post-discharge to bridge recurrence risk
- Rescue plan: Clear written instructions for outpatient acute medication use, including frequency limits
- Address medication overuse if present: discontinue offending agents; educate on MOH cycle
- Follow-up with headache specialist within 2 weeks (not 4 weeks) given high recurrence risk
- Headache diary to track recurrence and medication use post-discharge
- Return precautions: Return to ED if headache returns to severe/unremitting within 72 hours of discharge
Trial Evidence Summary
| Trial | Year | Intervention | Key Outcome |
|---|---|---|---|
| DHE IV for Intractable Migraine | 1986 | IV DHE + metoclopramide q8h vs IV diazepam | 89% vs 13% headache-free at 48h; hospital stay 3.8 vs 8.4 days |
| PROMISE-2 | 2020 | IV eptinezumab 100-300 mg | Effect observed Day 1 post-infusion; -7.7 to -8.2 MMD reduction |
| Nagy et al. (meta-analysis) | 2022 | IV DHE protocols (systematic review) | Confirmed efficacy across multiple protocols; supports inpatient use |
References
- Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
- Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine (DHE IV for Intractable Migraine). Neurology. 1986;36(7):995-997.
- Nagy AJ, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches: a systematic review and meta-analysis. Neurology. 2022;99(21):e2320-e2330.
- Lipton RB, et al. Eptinezumab in patients with chronic migraine (PROMISE-2). Neurology. 2020;94(13):e1365-e1377.
- Marmura MJ, et al. Intravenous lidocaine for refractory chronic daily headache: a retrospective case series. Headache. 2015;55(8):1131-1141.
- Schwenk ES, et al. Ketamine for refractory headache: a narrative review. Reg Anesth Pain Med. 2018;43(8):875-879.
- Orr SL, et al. Management of adults with acute migraine in the emergency department. Headache. 2016;56(6):911-940.